Potential of Glycyrrhiza in the prevention of colitis-associated colon cancer

被引:0
|
作者
Liu, Fang [1 ,2 ]
Gu, Zhili [2 ]
Yi, Feiyang [2 ]
Liu, Xue [2 ]
Zou, Wenxuan [2 ]
Xu, Qingxia [1 ]
Yuan, Yun [1 ]
Chen, Nianzhi [3 ]
Tang, Jianyuan [1 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610075, Peoples R China
[2] North Sichuan Med Coll, Nanchong, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 200000, Peoples R China
基金
中国博士后科学基金;
关键词
Glycyrrhiza; Colitis-associated Colon Cancer; Inflammatory Bowel Disease; Precancerous lesions; Dietary supplement; NF-KAPPA-B; COLORECTAL-CANCER; GLYCYRRHETINIC ACID; ULCERATIVE-COLITIS; SAFETY ASSESSMENT; INDUCED TOXICITY; GUT MICROBIOTA; CYCLE ARREST; UPLC-MS/MS; RAT PLASMA;
D O I
10.1016/j.fitote.2025.106398
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ethnopharmacological relevance: Glycyrrhiza, a legume native to the Mediterranean region, has a long history of ethnomedicinal use in China. Due to its antiviral, antibacterial, anti-inflammatory, antioxidant, antitumor, antiulcer, and hepatoprotective properties, Glycyrrhiza is widely utilized in the treatment of gastrointestinal disorders. The aim of the review: The specific mechanisms of the main active constituents of glycyrrhiza in the treatment of inflammatory bowel disease, precancerous lesions and colorectal cancer at all stages of the colitis-associated colon cancer "Inflammation-Dysplasia-Cancer" sequence, as well as its pharmacokinetics, toxicology, formulation improvements, and application studies, are reviewed to provide new insights and perspectives on glycyrrhiza as a dietary supplement to treat and prevent colitis-associated colon cancer. Materials and methods: Information on Glycyrrhiza was retrieved from electronic databases, including PubMed and Web of Science. Results: Glycyrrhiza is a well-established medicinal plant with significant potential for applications in both the food and pharmaceutical industries. Over 400 active constituents have been identified in Glycyrrhiza, including terpenoids, flavonoids, isoflavones, coumarins, and polyphenols. Numerous studies have demonstrated that Glycyrrhiza and its active compounds can inhibit the "Inflammation-Dysplasia-Cancer" progression of colitis associated colon cancer by mitigating inflammatory bowel disease, reducing the number of intestinal precan- cerous lesions, and counteracting colorectal cancer. Furthermore, derivatives and nanocarriers are crucial for the effective treatment of colitis-associated colon cancer using Glycyrrhiza and its active constituents. Conclusion: In conclusion, Glycyrrhiza is a plant with both medicinal and nutritional value, making it a potential food ingredient and dietary supplement for the treatment of colitis-associated colon cancer.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] MicroRNA targeting for the therapy of colitis-associated colon cancer.
    Polytarchou, Christos
    Hommes, Daniel W.
    Palumbo, Tiziana
    Hatziapostolou, Maria
    Koukos, Georgios
    van der Meulen-de Jong, Andrea E.
    Oikonomopoulos, Angelos
    van Deen, Welmoed K.
    Vorvis, Christina
    Koutsioumpa, Marina
    Birli, Eleni
    Choi, Jennifer
    Chang, Lin
    Anton, Peter A.
    Pothoulakis, Charalabos
    Verspaget, Hein W.
    Iliopoulos, Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [22] Surveillance for colitis-associated colon neoplasia
    Freeman, Hugh James
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (37) : 4646 - 4651
  • [23] Surveillance for colitis-associated colon neoplasia
    Hugh James Freeman
    World Journal of Gastroenterology, 2010, 16 (37) : 4646 - 4651
  • [24] Prevention of colitis-associated colorectal cancer with 8-hydroxydeoxyguanosine
    Ock, Chan Young
    Kim, Eun-Hee
    Hong, Kyung Sook
    Hahm, Ki-Baik
    Chung, Myung-Hee
    CANCER RESEARCH, 2011, 71
  • [25] Prevention of Colitis-Associated Colorectal Cancer with 8-Hydroxydeoxyguanosine
    Ock, Chan Young
    Kim, Eun-Hee
    Hong, Hua
    Hong, Kyung Sook
    Han, Young-Min
    Choi, Ki-Seok
    Hahm, Ki-Baik
    Chung, Myung-Hee
    CANCER PREVENTION RESEARCH, 2011, 4 (09) : 1507 - 1521
  • [26] Prevention of Colitis-Associated Cancer through Inhibiting SHh Signaling
    Kim, Yoon Jae
    Kangwan, Napapan
    Kim, Eun Hee
    Hahm, Ki Balk
    DIGESTION, 2014, 89 (01) : 77 - 77
  • [27] Prevention of Colitis-Associated Carcinogenesis with Infliximab
    Kim, Yoon Jae
    Hong, Kyung Sook
    Chung, Jun Won
    Kim, Ju Hyun
    Hahm, Ki Baik
    CANCER PREVENTION RESEARCH, 2010, 3 (10) : 1314 - 1333
  • [28] Unveiling the role of mast cells in colitis-associated mouse colon cancer
    Lecce, M.
    Molfetta, R.
    Milito, N. D.
    Scarno, G.
    Pietropaolo, G.
    Sciume, G.
    Santoni, A.
    Paolini, R.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 171 - 172
  • [29] Involvement of interleukin-21 in the regulation of colitis-associated colon cancer
    Stolfi, Carmine
    Rizzo, Angelamaria
    Franze, Eleonora
    Rotondi, Angela
    Fantini, Massimo Claudio
    Sarra, Massimiliano
    Caruso, Roberta
    Monteleone, Ivan
    Sileri, Pierpaolo
    Franceschilli, Luana
    Caprioli, Flavio
    Ferrero, Stefano
    MacDonald, Thomas T.
    Pallone, Francesco
    Monteleone, Giovanni
    JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (11): : 2279 - 2290
  • [30] Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer
    Pastille, Eva
    Frede, Annika
    McSorley, Henry J.
    Grab, Jessica
    Adamczyk, Alexandra
    Kollenda, Sebastian
    Hansen, Wiebke
    Epple, Matthias
    Buer, Jan
    Maizels, Rick M.
    Klopfleisch, Robert
    Westendorf, Astrid M.
    PLOS PATHOGENS, 2017, 13 (09)